Article
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
31 Aug 2021
Abstract excerpt
Plasmablastic lymphoma (PBL) represents a rare and aggressive lymphoma subtype frequently associated with immunosuppression. Clinically, patients with PBL are characterized by poor outcome. The current understanding of the molecular pathogenesis is limited. A hallmark of PBL represents its plasmacytic differentiation with loss of B-cell markers and, in 60% of cases, its association with Epstein-Barr virus (EBV)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
